Manipulation of the hepcidin pathway for therapeutic purposes

Haematologica

Volumn 98, Issue 11, 2013, Pages 1667-1676

  Fung, Eileen ^a   Nemeth, Elizabeta ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN RECEPTOR; FERROPORTIN ANTIBODY; FURSULTIAMINE; GENISTEIN; HEMOGLOBIN; HEMOJUVELIN ANTISENSE OLIGONUCLEOTIDE; HEPARIN; HEPCIDIN; HEPCIDIN AGONIST; HEPCIDIN ANTAGONIST; HEPCIDIN ANTIBODY; HORMONE ANALOG; HORMONE ANTAGONIST; INTERLEUKIN 6 ANTIBODY; IRON; LDN 193189; LY 2787106; MATRIPTASE 2 ANTISENSE OLIGODEOXYNUCLEOTIDE; MATRIPTASE 2 SMALL INTERFERING RNA; MINIHEPCIDIN; N BENZYL 2 CYANO 3 (3, 4 DIHYDROXYPHENYL) ACRYLAMIDE; NOX H94; PR 65; PRS 080; SMAD PROTEIN; SOLUBLE HEMOJUVELIN FC FUSION PROTEIN; TFR2 SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; DRUG MEGADOSE; ERYTHROPOIESIS; GENE MUTATION; GENETIC TRANSCRIPTION; HEMOCHROMATOSIS; HEMOSIDEROSIS; HUMAN; INFLAMMATION; IRON ABSORPTION; IRON BLOOD LEVEL; IRON OVERLOAD; IRON RESTRICTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANEMIA, IRON-DEFICIENCY; ANIMALS; HEPCIDINS; HOMEOSTASIS; HUMANS; IRON CHELATING AGENTS; IRON METABOLISM DISORDERS; IRON OVERLOAD; SIGNAL TRANSDUCTION;

EID: 84886991697     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.084624     Document Type: Review

References (108)

1. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med. 2011; 62: 347-60.
2. Andrews NC. Iron Deficiency and Related Disorders. In: Greer JP, Foerster J, eds. Wintrobe's Clinical Hematology. 12th ed. 2009. p. 810-34.
3. Brissot P, Ropert M, Le LC, Loreal O. Nontransferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta. 2012; 1820(3): 403-10.
4. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306(5704): 2090-3.
5. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab. 2005; 1(3): 191-200.
6. Qiao B, Sugianto P, Fung E, Del-Castillo-Rueda A, Moran-Jimenez MJ, Ganz T, et al. Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell Metab. 2012; 15(6): 918-24.
7. Preza GC, Pinon R, Ganz T, Nemeth E. Cellular catabolism of the iron-regulatory peptide hormone hepcidin. PLOS One. 2013; 8(3): e58934.
8. Steinbicker AU, Bartnikas TB, Lohmeyer LK, Leyton P, Mayeur C, Kao SM, et al. Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice. Blood. 2011; 118(15): 4224-30.
9. Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009; 41(4): 478-81.
10. Andriopoulos B Jr, Corradini E, Xia Y, Faasse SA, Chen S, Grgurevic L, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009; 41(4): 482-7.
11. Ramos E, Kautz L, Rodriguez R, Hansen M, Gabayan V, Ginzburg Y, et al. Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatology. 2011; 53(4): 1333-41.
12. Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006; 38(5): 531-9.
13. Papanikolaou G, Samuels ME, Ludwig EH, MacDonald ML, Franchini PL, Dube MP, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004; 36 (1): 77-82.
14. Corradini E, Meynard D, Wu Q, Chen S, Ventura P, Pietrangelo A, et al. Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology. 2011; 54(1): 273-84.
15. Goswami T, Andrews NC. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem. 2006; 281(39): 28494-8.
16. D'Alessio F, Hentze MW, Muckenthaler MU. The hemochromatosis proteins HFE, TfR2, and HJV form a membrane-associated protein complex for hepcidin regulation. J Hepatol. 2012; 57(5): 1052-60.
17. Corradini E, Rozier M, Meynard D, Odhiambo A, Lin HY, Feng Q, et al. Iron regulation of hepcidin despite attenuated Smad1, 5, 8 signaling in mice without transferrin receptor 2 or Hfe. Gastroenterology. 2011; 141(5): 1907-14.
18. Schmidt PJ, Fleming MD. Transgenic HFEdependent induction of hepcidin in mice does not require transferrin receptor-2. Am J Hematol. 2012; 87(6): 588-95.
19. Piperno A, Girelli D, Nemeth E, Trombini P, Bozzini C, Poggiali E, et al. Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood. 2007; 110(12): 4096-100.
20. Silvestri L, Pagani A, Nai A, De Domenico I, Kaplan J, Camaschella C. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 2008; 8(6): 502-11.
21. Zhang AS, Anderson SA, Wang J, Yang F, DeMaster K, Ahmed R, et al. Suppression of hepatic hepcidin expression in response to acute iron deprivation is associated with an increase of matriptase-2 protein. Blood. 2011; 117(5): 1687-99.
22. Finberg KE, Heeney MM, Campagna DR, Aydinok Y, Pearson HA, Hartman KR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet. 2008; 40(5): 569-71.
23. Enns CA, Ahmed R, Zhang AS. Neogenin interacts with matriptase-2 to facilitate hemojuvelin cleavage. J Biol Chem. 2012; 287(42): 35104-17.
24. Kautz L, Meynard D, Monnier A, Darnaud V, Bouvet R, Wang RH, et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood. 2008; 112(4): 1503-9.
25. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002; 110(7): 1037-44.
26. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006; 108(12): 3730-5.
27. Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007; 92(5): 583-8.
28. Kearney SL, Nemeth E, Neufeld EJ, Thapa D, Ganz T, Weinstein DA, et al. Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer. 2007; 48(1): 57-63.
29. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007; 13(9): 1096-101.
30. Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood. 2009; 114(1): 181-6.
31. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113(9): 1271-6.
32. Verga Falzacappa MV, Vujic SM, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007; 109(1): 353-8.
33. Armitage AE, Eddowes LA, Gileadi U, Cole S, Spottiswoode N, Selvakumar TA, et al. Hepcidin regulation by innate immune and infectious stimuli. Blood. 2011; 118(15): 4129-39.
34. Chung B, Verdier F, Matak P, Deschemin JC, Mayeux P, Vaulont S. Oncostatin M is a potent inducer of hepcidin, the iron regulatory hormone. FASEB J. 2010; 24(6): 2093-103.
35. Maes K, Nemeth E, Roodman GD, Huston A, Esteve F, Freytes C, et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood. 2010; 116(18): 3635-44.
36. Besson-Fournier C, Latour C, Kautz L, Bertrand J, Ganz T, Roth MP, et al. Induction of activin B by inflammatory stimuli up-regulates expression of the ironregulatory peptide hepcidin through Smad1/5/8 signaling. Blood. 2012; 120(2): 431-9.
37. Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet. 2003; 33(1): 21-2.
38. Nemeth E, Ganz T. Hepcidin and iron-loading anemias. Haematologica. 2006; 91(6): 727-32.
39. Pasricha SR, Frazer DM, Bowden DK, Anderson GJ. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with beta-thalassemia major: a longitudinal study. Blood. 2013; 122(1): 124-33.
40. Roy CN, Mak HH, Akpan I, Losyev G, Zurakowski D, Andrews NC. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood. 2007; 109(9): 4038-44.
41. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008; 112(10): 4292-7.
42. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002; 100(10): 3776-81.
43. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, et al. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4(6): 1051-6.
44. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009; 75(9): 976-81.
45. Wians FH Jr, Urban JE, Keffer JH, Kroft SH. Discriminating between iron deficiency anemia and anemia of chronic disease using traditional indices of iron status vs transferrin receptor concentration. Am J Clin Pathol. 2001; 115(1): 112-8.
46. Libregts SF, Gutierrez L, de Bruin AM, Wensveen FM, Papadopoulos P, van IW, et al. Chronic IFN-gamma production in mice induces anemia by reducing erythrocyte life span and inhibiting erythropoiesis through an IRF-1/PU. 1 axis. Blood. 2011; 118(9): 2578-88.
47. Prince OD, Langdon JM, Layman AJ, Prince IC, Sabogal M, Mak HH, et al. Late stage erythroid precursor production is impaired in mice with chronic inflammation. Haematologica. 2012; 97(11): 1648-56.
48. Nicolas G, Viatte L, Lou DQ, Bennoun M, Beaumont C, Kahn A, et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet. 2003; 34(1): 97-101.
49. Gardenghi S, Ramos P, Marongiu MF, Melchiori L, Breda L, Guy E, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice. J Clin Invest. 2010; 120(12): 4466-77.
50. Kim A, Fung E, Parikh S, Gabayan V, Nemeth E, and Ganz T. Detailed characterization of the mouse model of anemia of inflammation caused by heatkilled brucella abortus reveals multiple causes of anemia and partial dependence on hepcidin [abstract]. Am J Hematol. 2013; 5(88): E137.
51. Gardenghi S, Casu C, Renaud TM, Meloni A, Cooke KS, Sasu BJ, and others. Investigating the role of cytokines and hepcidin in anemia of inflammation [Abstract]. Am J Hematol. 2013; 5(88): E124.
52. Langdon J, Yates S, Femnou L, McCranor B, Xue QL, Vaulont S, and others. Hepcidindependent and hepcidin-independent regulation of erythropoiesis in a mouse model of anemia of chronic inflammation [abstract]. Am J Hematol. 2013; 5(88): E139.
53. Mayeur C, Steinbicker AU, Kolodziej SA, and Bloch KD. In a mouse model of chronic inflammation, liver-specific deletion of ALK3 (a BMP type I receptor) prevents the development of anemia of inflammation [abstract]. Am J Hematol 2013; 5(88): E29.
54. Barton JC. Chelation therapy for iron overload. Curr Gastroenterol Rep. 2007; 9(1): 74-82.
55. Porter JB. Optimizing iron chelation strategies in beta-thalassaemia major. Blood Rev. 2009; 23 Suppl 1: S3-S7.
56. Xiao JJ, Krzyzanski W, Wang YM, Li H, Rose MJ, Ma M, et al. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J 2010; 12(4): 646-57.
57. Preza GC, Ruchala P, Pinon R, Ramos E, Qiao B, Peralta MA, et al. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J Clin Invest 2011; 121(12): 4880-8.
58. Ramos E, Ruchala P, Goodnough JB, Kautz L, Preza GC, Nemeth E, et al. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood 2012; 120(18): 3829-36.
59. Nai A, Pagani A, Mandelli G, Lidonnici MR, Silvestri L, Ferrari G, et al. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia. Blood 2012; 119(21): 5021-9.
60. Guo S, Casu C, Gardenghi S, Booten S, Aghajan M, Peralta R, et al. Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice. J Clin Invest 2013; 123(4): 1531-41.
61. Schmidt PJ, Toudjarska I, Sendamarai AK, Racie T, Milstein S, Bettencourt BR, et al. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia. Blood 2013; 121(7): 1200-8.
62. Corradini E, Schmidt PJ, Meynard D, Garuti C, Montosi G, Chen S, et al. BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice. Gastroenterology 2010; 139(5): 1721-9.
63. Zhen AW, Nguyen NH, Gibert Y, Motola S, Buckett P, Wessling-Resnick M, et al. The Small Molecule Genistein Increases Hepcidin Expression in Human Hepatocytes. Hepatology. 2013.
64. Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2002; 17 (Suppl 11): 39-43.
65. Horl WH. Iron therapy for renal anemia: how much needed, how much harmful? Pediatr Nephrol. 2007; 22(4): 480-9.
66. Steinbrook R. Erythropoietin, the FDA, and oncology. N Engl J Med. 2007; 356(24): 2448-51.
67. Bennett CL, Spiegel DM, Macdougall IC, Norris L, Qureshi ZP, Sartor O, et al. A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012; 38(8): 783-96.
68. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, et al. Novel regulators of bone formation: molecular clones and activities. Science. 1988; 242(4885): 1528-34.
69. Poli M, Girelli D, Campostrini N, Maccarinelli F, Finazzi D, Luscieti S, et al. Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood. 2011; 117(3): 997-1004.
70. Poli, M., Girelli, D., Naggi, A., Campostrini, N., Asperti, M., Finazzi, D. and others. Identification of heparins without anticoagulant activity which inhibit hepcidin in vivo [abstract]. Am J Hematol. 2013; 5(88): E40.
71. Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood. 2005; 106(8): 2884-9.
72. Wu Q, Sun CC, Lin HY, Babitt JL. Repulsive guidance molecule (RGM) family proteins exhibit differential binding kinetics for bone morphogenetic proteins (BMPs). PLoS One. 2012; 7(9): e46307.
73. Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007; 117(7): 1933-9.
74. Theurl I, Schroll A, Sonnweber T, Nairz M, Theurl M, Willenbacher W, et al. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood. 2011; 118(18): 4977-84.
75. Nili M, Shinde U, Rotwein P. Soluble repulsive guidance molecule c/hemojuvelin is a broad spectrum bone morphogenetic protein (BMP) antagonist and inhibits both BMP2-and BMP6-mediated signaling and gene expression. J Biol Chem. 2010; 285(32): 24783-92.
76. Cuny GD, Yu PB, Laha JK, Xing X, Liu JF, Lai CS, et al. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett. 2008; 18(15): 4388-92.
77. Steinbicker AU, Sachidanandan C, Vonner AJ, Yusuf RZ, Deng DY, Lai CS, et al. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood. 2011; 117(18): 4915-23.
78. Sun CC, Vaja V, Chen S, Theurl I, Stepanek A, Brown DE, et al. A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrol Dial Transplant. 2013; 28(7): 1733-43.
79. Isis Pharmaceuticals. Xenon licenses antisense drug XEN701 from Isis and initiates preclinical toxicology studies. Updated 2013. Available from: http://ir. isispharm. com/phoenix. zhtml?c=222170& p=irol-newsArticle&ID=1828284&highlight=.
80. Akinc A, Chan-Daniels A, Sehgal A, Foster D, Bettencourt BR, Hettinger J, et al. Targeting the hepcidin pathway with RNAi therapeutics for the treatment of anemia. Blood. 2011; 21(118): 688.
81. Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010; 116(18): 3627-34.
82. Hashizume M, Uchiyama Y, Horai N, Tomosugi N, Mihara M. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. Rheumatol Int. 2010; 30(7): 917-23.
83. Schipperus M, Rijnbeek B, Reddy M, Qin X, Cornfield MJ. CNTO328 (Anti-IL-6 mAb) Treatment Is Associated with An Increase in Hemoglobin (Hb) and Decrease in Hepcidin Levels in Renal Cell Carcinoma (RCC) [abstract]. Blood. 2009; 22(114): 4045.
84. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, et al. A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease. Clin Cancer Res. 2013; 19(13): 3659-70.
85. Doyle MK, Rahman MU, Frederick B, Birbara CA, de Vries D, Toedter G, et al. Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. Rheumatology (Oxford) 2013; 52(7): 1214-9.
86. Zhang SP, Wang Z, Wang LX, Liu SJ. AG490: an inhibitor of hepcidin expression in vivo. World J Gastroenterol. 2011; 17(45): 5032-4.
87. Lang VR, Englbrecht M, Rech J, Nusslein H, Manger K, Schuch F, et al. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford) 2012; 51(5): 852-7.
88. van de Vosse E, van Agtmael MA. Targets of anticytokine therapy and the risk of infections in humans and mice. Curr Opin Rheumatol. 2007; 19(6): 626-35.
89. Elliott J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis. 2009; 16(2): 94-100.
90. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica. 2010; 95(3): 505-8.
91. Besarab A, Chernyavskaya EN, Motylev I, Evgeny S, Yampolskiy AF, Kumbar LM, et al. FG-4592, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, corrects anemia without iron supplementation in incident dialysis patients [abstract]. J Am Soc Nephrol. 2012; (23): 21A.
92. Besarab A, Hulter HN, Klaus S, Lee TT, Lilienfeld DE, Neff TB. et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD Patients [abstract]. J Am Soc Nephrol. 2010; (21): 95A.
93. Macdougall IC. New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis. 2012; 59(3): 444-51.
94. Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood. 2010; 115 (17): 3616-24.
95. Eli Lilly and Company. A Phase 1 Study of LY2787106 in Cancer and Anemia. Updated 2013. Available from: http://www. clinicaltrials. gov/ct2/show/N CT01340976.
96. Skerra A. Alternative binding proteins: anticalins-harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J. 2008; 275(11): 2677-83.
97. Hohlbaum A, Gille H, Christian J, Allersdorfer A, Jaworski J, Burrows J, et al. Iron mobilization and pharmacodynamic marker measurements in non-human primates following administration of PRS-080, a novel and highly specific anti-hepcidin therapeutic [abstract]. Am J Hematol. 2013; 5(88): E41.
98. Schwoebel F, van Eijk LT, Zboralski D, Sell S, Buchner K, Maasch C, et al. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood. 2013; 121 (12): 2311-5.
99. Riecke K, Zollner S, Boyce M, van Hecke B, Vauleon S, Summo L, et al. Single and repeated dose first-in-human study with the anti-hepcidin spiegelmer NOX-H94 [abstract]. Am J Hematol 2013; 5(88): E42.
100. van Eijk L, Swinkels DW, John A, Schwobel F, Fliegert F, Summo L, et al. Randomized double blind placebo controlled PK/PD study on the effects of a single intravenous dose of the anti-hepcidin spiegelmer NOXH94 on serum iron during experimental human endotoxemia [abstract]. Am J Hematol 2013; 5(88): E225.
101. Noxxon Pharma AG. Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer. Updated 2013. Available from: http://clinicaltrials. gov/show/NCT0169104 0.
102. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. The FASEB J. 2008; 22(3): 659-61.
103. Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol. 2010; 28(11): 1203-7.
104. Fung E, Sugianto P, Hsu J, Damoiseaux R, Ganz T, Nemeth E. High-throughput screening of small molecules identifies hepcidin antagonists. Mol Pharmacol. 2013; 83(3): 681-90.
105. Fernandes A, Preza GC, Phung Y, De Domenico I, Kaplan J, Ganz T, et al. The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood. 2009; 114(2): 437-43.
106. Leung DDM, Luan P, Menetta JV, Tang Y, Witcher D, inventors; Eli Lilly and Company, assignee. Anti-Ferroportin 1 Monoclonal Antibodies and Uses Thereof. Patent US 8183346 B2. 2012.
107. Eli Lilly and Company. A First Human Study of a Ferroportin Antibody. Updated 2011. Available from: http://www. clinicaltrials. gov/ct2/show/NCT01330953.
108. Guida C, Altamura S, Klein F, Boutros M, Hentze MW, Muckenthaler MU. Identification of novel regulators of ferroportin expression [abstract]. Am J Hematol 2013; 5(88): E128.